Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT, McDevitt MA, Kapur R, Carter M, Metcalfe DD, Takemoto CM.

Blood. 2011 Mar 31;117(13):3629-40. doi: 10.1182/blood-2010-07-293548. Epub 2011 Jan 27.

2.

The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Ainsua-Enrich E, Serrano-Candelas E, Álvarez-Errico D, Picado C, Sayós J, Rivera J, Martín M.

J Immunol. 2015 May 1;194(9):4309-18. doi: 10.4049/jimmunol.1402887. Epub 2015 Mar 25. Erratum in: J Immunol. 2017 Dec 27;:.

3.

A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors.

Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H.

Blood. 2005 Mar 15;105(6):2324-31. Epub 2004 Nov 23.

4.

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.

Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P.

Blood. 2007 Apr 1;109(7):3031-41.

5.

Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.

Jin B, Ding K, Pan J.

Mol Cancer Ther. 2014 May;13(5):1217-30. doi: 10.1158/1535-7163.MCT-13-0397. Epub 2014 Feb 19.

6.

Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.

De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA.

PLoS One. 2014 May 2;9(5):e96209. doi: 10.1371/journal.pone.0096209. eCollection 2014.

7.

Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Hoermann G, Cerny-Reiterer S, Perné A, Klauser M, Hoetzenecker K, Klein K, Müllauer L, Gröger M, Nijman SM, Klepetko W, Valent P, Mayerhofer M.

Am J Pathol. 2011 May;178(5):2344-56. doi: 10.1016/j.ajpath.2011.01.020. Epub 2011 Mar 31.

8.
9.

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.

Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL.

Cancer. 2006 Jul 15;107(2):345-51.

10.

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Smrž D, Bandara G, Zhang S, Mock BA, Beaven MA, Metcalfe DD, Gilfillan AM.

J Immunol Methods. 2013 Apr 30;390(1-2):52-62. doi: 10.1016/j.jim.2013.01.008. Epub 2013 Jan 25.

11.

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H.

Leuk Res. 2006 Nov;30(11):1365-70. Epub 2006 Jun 23.

PMID:
16797704
12.

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD.

Blood. 2004 Apr 15;103(8):3222-5. Epub 2003 Dec 24.

13.

Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice.

Tsujimura T, Morii E, Nozaki M, Hashimoto K, Moriyama Y, Takebayashi K, Kondo T, Kanakura Y, Kitamura Y.

Blood. 1996 Aug 15;88(4):1225-33.

14.

Eosinophilia in mast cell disease.

Kovalszki A, Weller PF.

Immunol Allergy Clin North Am. 2014 May;34(2):357-64. doi: 10.1016/j.iac.2014.01.013. Epub 2014 Mar 13. Review.

15.

Resistance to c-KIT kinase inhibitors conferred by V654A mutation.

Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK.

Mol Cancer Ther. 2007 Mar;6(3):1159-66.

16.

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.

Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD.

Exp Hematol. 2003 Aug;31(8):686-92.

PMID:
12901973
17.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG.

Blood. 2005 Jul 15;106(2):721-4. Epub 2005 Mar 24.

18.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.

Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16.

19.

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.

de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte AS, Barra FF, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Olalla Saad ST, Traina F.

Leuk Res. 2014 Oct;38(10):1245-51. doi: 10.1016/j.leukres.2014.07.010. Epub 2014 Aug 1.

20.

Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Chan EC, Bai Y, Kirshenbaum AS, Fischer ER, Simakova O, Bandara G, Scott LM, Wisch LB, Cantave D, Carter MC, Lewis JC, Noel P, Maric I, Gilfillan AM, Metcalfe DD, Wilson TM.

J Allergy Clin Immunol. 2014 Jul;134(1):178-87. doi: 10.1016/j.jaci.2013.12.1090. Epub 2014 Feb 28.

Supplemental Content

Support Center